|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Prepaid and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Deferred offering costs | ||||||||||||||||||||
| Operating lease right-of-use asset | ||||||||||||||||||||
| Security deposit | ||||||||||||||||||||
| Patents, net | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Accrued litigation settlement | ||||||||||||||||||||
| Accrued liabilities - related parties | ||||||||||||||||||||
| Accrued compensation | ||||||||||||||||||||
| Operating lease liability - current | ||||||||||||||||||||
| Notes payable | ||||||||||||||||||||
| Loans payable - related parties | ||||||||||||||||||||
| Convertible notes payable - related party, net of debt discount | ||||||||||||||||||||
| Convertible notes payable, net of debt discount | ||||||||||||||||||||
| Derivative liability | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Notes payable - related party, long-term, net of debt discount | ||||||||||||||||||||
| Operating lease liability - long-term | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| Commitments and Contingencies | ||||||||||||||||||||
| Preferred stock, value | ||||||||||||||||||||
| Series A Convertible Preferred Stock | ||||||||||||||||||||
| Total preferred stock, value | ||||||||||||||||||||
| Common Stock - $0.001 par value, 300,000,000 shares Authorized, 261,585,588 and 258,690,253 shares issued and outstanding at June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Subscription Receivable | ||||||||||||||||||||
| Additional Paid-In Capital | ||||||||||||||||||||
| Accumulated Deficit | ||||||||||||||||||||
| Total Stockholders' Deficit | ||||||||||||||||||||
| TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | ||||||||||||||||||||
Loading...
